Call for Abstract

2nd International Conference on Clinical & Cellular Immunology, will be organized around the theme Disseminating the New Trends in Immunology

Immunology Summit-2013 is comprised of 17 tracks and 116 sessions designed to offer comprehensive sessions that address current issues in Immunology Summit-2013.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Infection, allergies and immune response
  • Track 1-2Chemical signals and pathways in immune system
  • Track 1-3Veterinary immunology
  • Track 1-4Host defense mechanisms: Humans, animals, prokaryotes and invertebrates
  • Track 1-5Clinical immunomics
  • Track 1-6Innate immunity, metabolism, and immunology
  • Track 1-7Platelet immunology
  • Track 1-8Immuno-informatics
  • Track 2-1Molecular pathways for human natural killer cells
  • Track 2-2Structural and functional parameters of antimicrobial peptides (AMPs)
  • Track 2-3Pathogenesis of diseases
  • Track 2-4Innate-adaptive interactions
  • Track 2-5Approaches to study innate immunity
  • Track 2-6Advancing against asthma
  • Track 3-1 Autoimmune diseases: Organ and tissue
  • Track 3-2Major histocompatibility complex classes
  • Track 3-3Role of Th17 cells and their importance
  • Track 3-4 Gastro intestinal autoimmunity, skin and autoimmunity
  • Track 3-5Systemic lupus erythematosus
  • Track 3-6Immune responses in arthritis
  • Track 3-7Infection and autoimmunity, and metabolic disorders
  • Track 3-8Multiple sclerosis, and mislenious autoimmune diseases
  • Track 3-9Inflammatory bowel disease
  • Track 4-1Stem cell therapy
  • Track 4-2Alternative targets for immunointervention
  • Track 4-3Clinical strategies to induce transplantation tolerance
  • Track 4-4Immunomodulation and drug discovery
  • Track 4-5Stem cell therapy, and soluble mediators and signaling
  • Track 4-6Induced immunosuppression therapy and cellular mechanisms
  • Track 4-7Immunotherapies and rheumatoid arthritis
  • Track 5-1Hepatitis
  • Track 5-2Tuberculosis
  • Track 5-3Influenza
  • Track 5-4HIV/AIDS and Chagas disease
  • Track 5-5Malaria
  • Track 5-6Human papilloma virus
  • Track 5-7 Diabetes
  • Track 6-1Tumorigenesis and tumor suppression or cancer immune prevention
  • Track 6-2Epithelial stem cell cancer
  • Track 6-3Interplay of cancer stem cells and metastasis
  • Track 6-4Advances in imaging and detection of cancer stem cells and metastatic precursors
  • Track 6-5Model studies for hematopoietic microenvironments
  • Track 6-6Genetic and epigenetic regulation of cancer cells
  • Track 6-7Cancer surveillance : Metastasis and cancer therapy
  • Track 6-8Apoptosis and current research
  • Track 7-1 Recombinant vaccines and immunotherapeutics
  • Track 7-2Cancer vaccines
  • Track 7-3Bacterial and viral vaccines
  • Track 7-4Immunological adjuvants
  • Track 7-5T-Cell vaccines
  • Track 7-6Synthetic vaccines, and contraceptive vaccines
  • Track 7-7Vaccine safety
  • Track 7-8Anti-inflammatory drugs and antiretroviral therapy
  • Track 8-1Osteoimmunology
  • Track 8-2Nano-medicine immunology
  • Track 8-3Mucosal immunology and translational immunology
  • Track 8-4Autophagy in immune regulation
  • Track 8-5Immune tolerance in pregnancy
  • Track 8-6Testicular immunology
  • Track 8-7Immunocontraception
  • Track 9-1RISET biomarkers
  • Track 9-2ITN biomarkers
  • Track 9-3Hybridoma technology
  • Track 9-4Assays for immunology
  • Track 9-5 Immunophenotyping: Flow cytometry and immunoelectrophoresis
  • Track 9-6Biomarkers and immune-modulating therapies
  • Track 9-7ITN biomarkers, and immunological biomarkers of tuberculosis
  • Track 10-1Immune system regulation
  • Track 10-2Transplantational immunology
  • Track 10-3Immune rejection: Novel therapeutic targets
  • Track 10-4Transplantation: Genetics and HLA system
  • Track 10-5Prolonging graft survival: Immunosuppressive drugs and research
  • Track 10-6Molecular signatures of tolerance : Islet transplantation
  • Track 10-7Memory T cell responses
  • Track 11-1Ethical issues in immunology: Alternatives to animals
  • Track 11-2Importance of the use of animals in immunological research and drug development
  • Track 11-3Other moral issues in immunological research
  • Track 11-4Current legislation on clinical research trials
  • Track 11-5Medical and comparative¬†ethics
  • Track 12-1Neuroimmunological disorders
  • Track 12-2Acute disseminated encephalomyelitis
  • Track 12-3Multiple sclerosis, neuromyelitis optica and transverse myelitis
  • Track 12-4Neurodegenerative disorders
  • Track 12-5Neurodevelopmental disorders
  • Track 12-6Neural stem cell fate
  • Track 12-7Epigenetics of neuroimmunology
  • Track 12-8Cell death and immunity
  • Track 13-1Therapeutic applications of cytokines and chemokines
  • Track 13-2Cytokines and metabolism
  • Track 13-3Cytokines in health and disease
  • Track 13-4Mucosal homeostasis and inflammation
  • Track 13-5The interferons, growth factors, and TNF family
  • Track 13-6Hematopoietic growth factors
  • Track 13-7Interleukins: TIR-receptor families
  • Track 13-8Recently discovered cytokines
  • Track 13-9Common cytokine receptor gamma-chain cytokine family
  • Track 14-1Pediatric allergy and current research
  • Track 14-2Food allergy: Allergens and environmental factors
  • Track 14-3Genetic basis
  • Track 14-4Diagnosis and pathophysiology
  • Track 15-1Molecular aspects of primary immunodeficiency
  • Track 15-2Autoimmunity in primary immunodeficiency
  • Track 15-3Humoral immune deficiency
  • Track 15-4T cell deficiency, differentiation and plasticity
  • Track 15-5Complement deficiency
  • Track 15-6Neutropenia and asplenia
  • Track 16-1Antibiotics and immune system
  • Track 16-2Infectious diseases and Medicine
  • Track 16-3Immuno suppressive drugs
  • Track 16-4Immune rejection
  • Track 17-1Rheumatoid arthritis and osteoarthritis
  • Track 17-2 New approaches in rheumatology therapy
  • Track 17-3Juvenile idiopathic arthritis
  • Track 17-4Osteoporosis in rheumatology
  • Track 17-5Disease modifying anti-rheumatic drugs (DMARDs)
  • Track 17-6 Use of glucocorticoids and NSAIDs in rheumatic diseases